Upadacitinib for Crohn's Disease and Ulcerative Colitis Treatment: Hitting the Selective JAKpot

Gastroenterology. 2021 Apr;160(5):1472-1474. doi: 10.1053/j.gastro.2020.04.034. Epub 2020 Apr 18.

Authors

Tommaso Lorenzo Parigi¹, Ferdinando D'Amico², Silvio Danese³

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
² Department of Biomedical Sciences, Humanitas University and, IBD center, Humanitas Clinical and Research Center, Milan, Italy.
³ Department of Biomedical Sciences, Humanitas University and, IBD center, Humanitas Clinical and Research Center, Milan, Italy. Electronic address: sdanese@hotmail.com.

PMID: 32311362
DOI: 10.1053/j.gastro.2020.04.034

No abstract available

Publication types

Editorial
Comment

MeSH terms

Colitis, Ulcerative* / diagnosis
Colitis, Ulcerative* / drug therapy
Crohn Disease* / diagnosis
Crohn Disease* / drug therapy
Heterocyclic Compounds, 3-Ring
Humans

Substances

Heterocyclic Compounds, 3-Ring
upadacitinib